Vise Technologies Inc. Has $2.48 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Vise Technologies Inc. lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 30.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 26,838 shares of the biopharmaceutical company's stock after buying an additional 6,276 shares during the quarter. Vise Technologies Inc.'s holdings in Gilead Sciences were worth $2,479,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of GILD. HHM Wealth Advisors LLC grew its position in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 154 shares during the period. YANKCOM Partnership acquired a new stake in Gilead Sciences in the 4th quarter valued at $28,000. Crews Bank & Trust acquired a new stake in Gilead Sciences in the 4th quarter valued at $31,000. Stephens Consulting LLC grew its position in Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 260 shares during the period. Finally, Newbridge Financial Services Group Inc. acquired a new stake in Gilead Sciences in the 4th quarter valued at $33,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total value of $266,000.00. Following the sale, the chief financial officer now directly owns 168,174 shares in the company, valued at approximately $17,893,713.60. The trade was a 1.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders have sold 22,929 shares of company stock worth $2,634,220. Company insiders own 0.27% of the company's stock.

Analysts Set New Price Targets

GILD has been the subject of several research reports. Oppenheimer reduced their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research report on Wednesday. The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Finally, DZ Bank raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a report on Thursday, February 13th. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Trading Down 0.9%

NASDAQ GILD opened at $106.74 on Friday. The stock has a market capitalization of $132.78 billion, a price-to-earnings ratio of 288.49, a PEG ratio of 0.71 and a beta of 0.26. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The business's fifty day moving average is $105.33 and its 200-day moving average is $100.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business's revenue for the quarter was down .3% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.32) EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.96%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio is currently 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.